Association of SRD5A2 genotype and pathological characteristics of prostate tumors

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1626-1630

  Jaffe, Julie M ^a,b   Malkowicz, S Bruce ^b   Walker, Amy H ^b   MacBride, Sam ^b   Peschel, Richard ^a   Tomaszewski, John ^b   Van Arsdalen, Keith ^b   Wein, Alan J ^b   Rebbeck, Timothy R ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ARTICLE; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY;

ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; DNA; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; VARIATION (GENETICS);

EID: 0034654218     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bruchovsky, N. Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology, 89: 1212-1222, 1971.
2. Isaacs, J. T., and Coffey, D. S. Changes in dihydrotestosterone metabolism asssociated with the development of canine benign prostatic hyperplasia. Endocrinology, 108: 445-453, 1981.
3. Issacs, J. T., and Coffey, D. S. Androgen metabolism of the prostate: new concepts related to normal and abnormal growth. In: J. E. Everett , G. Altwein , G. Bartsch, and G. H. Jacoby (eds.), Antihormones. Bedeutung in der Urologie. Munich: W. Zuckschwerdt Verlag, 1981.
4. Bruchovsky, N., and Wilson, J. D. The conversion of testosterone to 5-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 243: 2012-2021, 1968.
5. Bruchovsky, N., and Wilson, J. D. The intranuclear binding of testosterone to 5-androstan-17b-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 243: 5953-5960, 1968.
6. Coffey, D. S. Androgen action and the sex accessory tissues. In: E. Knobil, J. J. Neill, and L. L. Ewing, (eds.), The Physiology of Reproduction, pp. 1081-1118. New York: Raven Press, 1988.
7. Coffey, D. S. The molecular biology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Disease, pp. 28-56. Philadelphia: Saunders, 1993.
8. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5-α reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
9. Lookingbill, D. P., Demers, L. M., Wang, C., Leung, A., Rittmaster, R. S., and Santen, R. J. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab., 72: 1242-1248, 1991.
10. Ross, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J. K. V., Yu, M. C., Feigelson, H., Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58: 4497-4504, 1998.
11. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. V. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
12. Makridakis, N. M., and Reichardt, J. K. V. Kinetic and biochemical characterization of naturally occurring variants of the steroid 5a-reductase type II (SRD5A2) gene. Am. J. Hum. Genet., 64: A373, 1998.
13. Reichardt, J., Makridakis, N., Pike, M., Crocitto, L., Kolonel, L., Ross, R., and Henderson, B. The A49T mutation in the SRD5A2 gene increases risk for aggressive prostate cancer and prostatic steroid 5-α reductase activity. Am J. Hum. Genet., 61: A209, 1997.
14. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitlo, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. Association of mis-sense substitution in SRD5A2 gene with prostate career in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.
15. Richards, B., Skolestsky, J., Shuber, A. P., Balfour, R., Stern, R. C., and Dorkin, H. L. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs Hum. Mol. Genet., 2: 159-163, 1993.
16. Gleason, D. F. The Veteran's Administration cooperative urologie research group: histologic grading and clinical staging of prostatic carcinoma. In: M. Tannenbaum (ed.), Urologic Pathology: The Prostate, pp. 171-198. Philadelphia: Lea and Febiger, 1977.
17. Sakr, W. A., Wheeler, T. M., Blute, M., Bodo, M., Calle-Rodrique, R., Henson, D. E. Mostofi, F. K., Seiffert, J., Wojno, W., and Zincke, H. International consultation on prostatic intraepihelial neoplasia and pathologic staging of prostatic carcinoma: staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer (Phila.), 78: 366-368, 1996.
18. Vilchis, F., Hernandez, D., Canto, P., Mendez, J. P., and Chavez, B. Codon 89 polymorphism of the human 5a-steroid reductase type 2 gene. Clin. Genet., 51: 399-402, 1997.
19. Kupelian, P. A., Katcher, J., Levin, H. S., and Klein, E. A. State T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int. J. Radial. Oncol. Biol. Phys., 37: 1043-1052, 1997.
20. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner, N. E., Venkatramen, E. S., Reuter, V. E., Fair, W. R., Ling, C. C., and Fuks, Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 41: 491-500, 1998.
21. Walsh, P. C. Radical Prostatectomy. In: L. Dennis (ed.), Prostate Cancer 2000, p. 52. New York: Spinger Verlag.
22. Preston-Martin, S., Pike, M. C., Ross, R. K., and Henderson, B. E. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ. Health Perspect., 101: 137-138, 1993.
23. Ross, R. K., Coetzee, G. A., Pearce, C. L., Reichardt, J. K. V., Bretsky, P., Kolonel, L. N., Henderson, B. E., Lander, E., Altshuler, D., and Daley, G. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Eur. Urol., 35: 355-361, 1999.
24. Zaridze, D. G., and Boyle, P. Cancer of the prostate: epidemiology and aetiology. Br. J. Urol., 59: 493-502, 1987.
25. Lamb, J. C., Levy, M. A., Johnson, R. K., and Isaacs, J. T. Response of rat and human prostatic cancers 10 the novel 5a-reductase inhibitor. SK&F 105657. Prostate, 21: 15-34, 1992.
26. Kadohama, N., Karr, J. P., Murphy, G. P., and Sandberg, A. A. Selective inhibition of prostatic tumor 5-α-reductase by a 4-methyt-4 aza steroid. Cancer Res., 44: 4947-4954, 1984.
27. Ross, R. K., and Schottenfeld, D. Prostate cancer. In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, pp. 1180-1206. New York: Oxford University Press, 1996.
28. Epstein, J. I., Pizov, G., and Walsh, P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (Phila.), 71: 3582-3593, 1993.
29. Watson, R. B., Civantos, F., and Soloway, M. S. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology, 48: 80-90, 1996.
30. D'Amico, A. V., Whittington, R., Malkowicz, B. S., Schultz, D., Schnall, M., Tomaszewski, J. E., and Wein, A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131-138, 1995.
31. McNeal, J. E., Kindrachuk, R. A., and Freiha, F. S. Patterns of progression in prostate cancer. Lancet, 1: 60-63, 1986.
32. McNeal, J. E., Villers, A. A., and Redwine, E. A., Capsular penetration in prostate cancer: significance for natural history and treatment. Am. J. Surg. Pathol., 14: 240-247, 1990.
33. Epstein, J. I., Carmichael, M. J., Pizov, G., and Walsh, P. C. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up. J. Urol., 150: 135-141, 1993.
34. Ohori, M., Wheeler, T. M., Kattan, M. W., Goto, Y., and Scardino, P. T. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818-1824, 1995.
35. Presti, J. C., Fair, W. R., and Andriole, G. Multicenter randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on state D prostate cancer. J. Urol., 148: 1201-1204, 1992.
36. Andriole, G., Lieber, M., and Smith, J. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology, 45: 491-497, 1995.
37. Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S., Coltman, C. A., Brawley, O. W., and Ford, L. G. Design of the prostate cancer prevention trial (PCPT). Controllerd Clin. Trials, 16: 150-163, 1995.